{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:10:03Z","timestamp":1756825803661,"version":"3.44.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,2]]},"DOI":"10.7759\/cureus.91475","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T14:30:39Z","timestamp":1756823439000},"source":"Crossref","is-referenced-by-count":0,"title":["Innovation in Onychomycosis Treatment Through Creative Compounding"],"prefix":"10.7759","author":[{"given":"Kristine","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Gorski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian P","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.062","article-title":"Onychomycosis: clinical overview and diagnosis","volume":"80","author":"Lipner SR","year":"2019","unstructured":"Lipner SR, Scher RK. Onychomycosis: clinical overview and diagnosis. J Am Acad Dermatol. 2019, 80:835-51. 10.1016\/j.jaad.2018.03.062","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01107.x","article-title":"Toenail onychomycosis: an important global disease burden","volume":"35","author":"Thomas J","year":"2010","unstructured":"Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010, 35:497-519. 10.1111\/j.1365-2710.2009.01107.x","journal-title":"J Clin Pharm Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpm.2016.02.001","article-title":"Onychomycosis: evaluation, treatment options, managing recurrence, and patient outcomes","volume":"33","author":"Vlahovic TC","year":"2016","unstructured":"Vlahovic TC. Onychomycosis: evaluation, treatment options, managing recurrence, and patient outcomes. Clin Podiatr Med Surg. 2016, 33:305-18. 10.1016\/j.cpm.2016.02.001","journal-title":"Clin Podiatr Med Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1800","article-title":"Fungal nail infection: diagnosis and management","volume":"348","author":"Eisman S","year":"2014","unstructured":"Eisman S, Sinclair R. Fungal nail infection: diagnosis and management. BMJ. 2014, 348:g1800. 10.1136\/bmj.g1800","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103844","article-title":"Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection","volume":"29","author":"Malallah OS","year":"2024","unstructured":"Malallah OS, Coleman L, Nasereddin SM, Lockhat M, Chen T, Jones SA. Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection. Drug Discov Today. 2024, 29:103844. 10.1016\/j.drudis.2023.103844","journal-title":"Drug Discov Today"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7190.1031","article-title":"Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis","volume":"318","author":"Evans EG","year":"1999","unstructured":"Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. BMJ. 1999, 318:1031-5. 10.1136\/bmj.318.7190.1031","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.3.353","article-title":"Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study","volume":"138","author":"Sigurgeirsson B","year":"2002","unstructured":"Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol. 2002, 138:353-7. 10.1001\/archderm.138.3.353","journal-title":"Arch Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.12.1551","article-title":"How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data","volume":"134","author":"Epstein E","year":"1998","unstructured":"Epstein E. How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. Arch Dermatol. 1998, 134:1551-4. 10.1001\/archderm.134.12.1551","journal-title":"Arch Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04639.x","article-title":"Long-term results in patients with onychomycosis treated with terbinafine or itraconazole","volume":"146","author":"Heikkil\u00e4 H","year":"2002","unstructured":"Heikkil\u00e4 H, Stubb S. Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br J Dermatol. 2002, 146:250-3. 10.1046\/j.1365-2133.2002.04639.x","journal-title":"Br J Dermatol"},{"key":"ref10","article-title":"Terbinafine","author":"Maxfield L","year":"2023","unstructured":"Maxfield L, Preuss CV, Bermudez R. Terbinafine. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref11","unstructured":"Terbinafine (oral route) description and brand names. (2025). Accessed. April 25, 2025: https:\/\/www.mayoclinic.org\/drugs-supplements\/terbinafine-oral-route\/description\/drg-20066265."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11100548","article-title":"Preparation, characterisation, and topical delivery of terbinafine","volume":"11","author":"Hossain AS","year":"2019","unstructured":"Hossain AS, Sil BC, Iliopoulos F, Lever R, Hadgraft J, Lane ME. Preparation, characterisation, and topical delivery of terbinafine. Pharmaceutics. 2019, 11:548. 10.3390\/pharmaceutics11100548","journal-title":"Pharmaceutics"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229414","article-title":"Assessment of the nail penetration of antifungal agents with different physicochemical properties","author":"Davies-Strickleton H","year":"2020","unstructured":"Davies-Strickleton H, Cook J, Hannam S, et al.. Assessment of the nail penetration of antifungal agents with different physicochemical properties. PLoS One. 2020, 10.1371\/journal.pone.0229414","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000521703","article-title":"Complementary and alternative therapies for onychomycosis: a systematic review of the clinical evidence","volume":"8","author":"Nickles MA","year":"2022","unstructured":"Nickles MA, Lio PA, Mervak JE. Complementary and alternative therapies for onychomycosis: a systematic review of the clinical evidence. Skin Appendage Disord. 2022, 8:269-79. 10.1159\/000521703","journal-title":"Skin Appendage Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S69596","article-title":"Efinaconazole in the treatment of onychomycosis","volume":"8","author":"Lipner SR","year":"2015","unstructured":"Lipner SR, Scher RK. Efinaconazole in the treatment of onychomycosis. Ther Clin Risk Manag. 2015, 8:163-72. 10.2147\/IDR.S69596","journal-title":"Ther Clin Risk Manag"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2011.01.100124","article-title":"Novel treatment of onychomycosis using over-the-counter mentholated ointment: a clinical case series","volume":"24","author":"Derby R","year":"2011","unstructured":"Derby R, Rohal P, Jackson C, Beutler A, Olsen C. Novel treatment of onychomycosis using over-the-counter mentholated ointment: a clinical case series. J Am Board Fam Med. 2011, 24:69-74. 10.3122\/jabfm.2011.01.100124","journal-title":"J Am Board Fam Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/397426-innovation-in-onychomycosis-treatment-through-creative-compounding","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T14:30:40Z","timestamp":1756823440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/397426-innovation-in-onychomycosis-treatment-through-creative-compounding"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.91475","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,2]]}}}